Loading...
XNAS
CLPT
Market cap384mUSD
Dec 05, Last price  
13.54USD
1D
-3.70%
1Q
22.53%
Jan 2017
298.24%
IPO
247.18%
Name

Clearpoint Neuro Inc

Chart & Performance

D1W1MN
XNAS:CLPT chart
P/E
P/S
12.26
EPS
Div Yield, %
Shrs. gr., 5y
15.49%
Rev. gr., 5y
22.85%
Revenues
31m
+31.04%
2,669,4503,818,1665,058,2353,930,5753,604,4824,594,1925,749,4547,379,5257,353,26611,216,93712,829,00016,299,00020,551,00023,955,00031,390,000
Net income
-19m
L-14.37%
-9,454,235-8,311,411-5,707,136-7,086,274-4,524,732-8,449,246-8,069,895-7,167,353-6,163,469-6,504,010-9,108,000-15,320,000-16,538,000-22,089,000-18,914,000
CFO
-9m
L-34.77%
-7,707,253-6,239,595-7,433,816-7,777,931-7,250,303-8,637,734-5,820,043-5,992,511-4,630,592-2,849,514-7,808,000-12,697,000-16,167,000-13,720,000-8,950,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
IPO date
Jul 03, 2019
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT